Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 17/20 | 0.56 |
| ▸ | MAOB | P27338 | 17/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15818207 | 0.93 | MAOB (0.60) | MAOAMAOB | |
| SCHEMBL17361548 | 0.87 | MAOB (0.54) | MAOAMAOB | |
| SCHEMBL10682934 | 0.83 | MAP2K1 (0.55) | MAOAMAOB | |
| SCHEMBL7651036 | 0.83 | MAOA (0.56) | MAOAMAOBPARP15PARP10HRH3 | |
| SCHEMBL10680049 | 0.82 | MAOA (0.54) | MAOAMAOBHRH3 | |
| SCHEMBL1034102 | 0.82 | HSD17B1 (0.51) | MAOAMAOBPARP15PARP10HRH3 | |
| SCHEMBL15839935 | 0.79 | MAOB (0.62) | MAOAMAOBHRH3 | |
| SCHEMBL7777400 | 0.79 | MAOB (0.58) | MAOAMAOB | |
| SCHEMBL18616171 | 0.79 | HRH3 (0.56) | MAOAMAOBPARP15PARP10HRH3 | |
| SCHEMBL10249569 | 0.78 | MAOA (0.61) | MAOAMAOBPARP15PARP10HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6482852-B2 | UE TREATING PROLIFERATIVE DISEASE, CANCER, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, ALLERGIES, OR CARDIOVASCULAR DISEASE; INHIBITION OF SH2-MEDIATED SIGNALING | ARIAD PHARMACEUTICALS, INC. | 2002-11-19 | — | — | US | disclosed |
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | ARIAD PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1129068-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITION CONTAINING THEM AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027802-A1 | BICYCLIC SIGNAL TRANSDUCTION INHIBITORS, COMPOSITIONS CONTAINING THEM & USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137941-A1 | Ue treating proliferative disease, cancer, restenosis, osteoporosis, inflammation, allergies, or cardiovascular disease; inhibition of SH2-mediated signaling | GRB2, LCK, PTK2 | MAOA 3051/4885MAOB 2687/4885PARP15 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.